Effect of vitamin D supplementation on nonalcoholic fatty liver disease in type 2 diabetic patients

Investigation of the effect of vitamin D supplementation on improvement of liver function test in type 2 diabetic patients who have both vitamin D deficiency and nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014020816528N1

Enrollment

115

Registered

2014-05-03

Start date

2014-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

In the intervention group vitamin D pearl (50000 IU) is administered orally one pearl per week for 12 weeks.

Treatment - Drugs

In the intervention group vitamin D pearl (50000 IU) is administered orally one pearl per week for 12 weeks

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: known case of type II diabetes who have been treated for at least 6 months exclusion criteria: positive history of alcohol use; positive history of hepatitis B or C; chronic liver or renal disease; consumption of drugs known to cause fatty liver change (such as estrogen, metotrexate, Tamoxifen, Tetracyclin, Oral contraceptive pills, sodium valporate); pregnancy or lactation; positive history of thyroid disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver enzymes(AST, ALT, GGT). Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
Lipid profile ( cholesterol, HDL, LDL, TG). Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: spectrophotometry.;HbA1C. Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: HPLC.;(fasting blood sugar) FBS. Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: spectrophotometry.	—

Measure

Time frame

Lipid profile ( cholesterol, HDL, LDL, TG). Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: spectrophotometry.;HbA1C. Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: HPLC.;(fasting blood sugar) FBS. Timepoint: at the begining of the study and 1 week after the last dose of vitamin D supplement. Method of measurement: spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Dabbaghmanesh

Shahrekord university of medical sciences, Shahrekord, Iran

dabbaghmanesh.alireza@yahoo.comsharareh.roshanzamir@gmail.com+98 917 711 1359

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026